Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 2
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 177
- Registration Number
- NCT00154401
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Zilina, Slovakia
Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 226
- Registration Number
- NCT00154414
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Use of NovoSeven® in Active Variceal Bleeding
Phase 2
Completed
- Conditions
- CirrhosisAcquired Bleeding Disorder
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 265
- Registration Number
- NCT00154492
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Oxford, United Kingdom
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Phase 3
Completed
- Conditions
- Acquired Bleeding DisorderIntracerebral Haemorrhage
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 829
- Registration Number
- NCT00127283
- Locations
- 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand
Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2Delivery Systems
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT00127296
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, San Antonio, Texas, United States
Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury
Completed
- Conditions
- TraumaAcquired Bleeding Disorder
- Interventions
- Drug: activated recombinant human factor VII
- First Posted Date
- 2005-07-27
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 63
- Registration Number
- NCT00124293
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Mississauga, Canada
Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury
Phase 2
Completed
- Conditions
- Acquired Bleeding DisorderTrauma
- First Posted Date
- 2005-07-25
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 96
- Registration Number
- NCT00123591
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Taoyuan, Taiwan
Novofine Autocover Safety Needle Versus BD Safety Glide
Phase 4
Completed
- Conditions
- DiabetesHealthcare ProfessionalsDelivery Systems
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 83
- Registration Number
- NCT00121355
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States
Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- First Posted Date
- 2005-07-08
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 520
- Registration Number
- NCT00117780
- Locations
- 🇱🇺
Novo Nordisk Investigational Site, Luxembourg, Luxembourg
A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2Delivery Systems
- First Posted Date
- 2005-06-27
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 71
- Registration Number
- NCT00115973
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath